Back to Search
Start Over
Developing a new national MDMA policy:Results of a multi-decision multi-criterion decision analysis
- Source :
- Amsterdam, J V, Peters, G-J Y, Pennings, E, Blickman, T, Hollemans, K, Breeksema, J J J, Ramaekers, J G, Maris, C, Bakkum, F V, Nabben, T, Scholten, W, Reitsma, T, Noijen, J, Koning, R & Brink, W V D 2021, ' Developing a new national MDMA policy : Results of a multi-decision multi-criterion decision analysis ', Journal of Psychopharmacology, vol. 35, no. 5, 0269881120981380, pp. 537-546 . https://doi.org/10.1177/0269881120981380, Journal of Psychopharmacology, 35(5):0269881120981380, 537-546. SAGE Publications Ltd, Journal of Psychopharmacology, 35(5), 537-546. SAGE Publications Inc., Journal of psychopharmacology (Oxford, England), 35(5), 537-546. SAGE Publications Ltd, Journal of Psychopharmacology (Oxford, England), Journal of Psychopharmacology, 35(5), 537-546. SAGE Publications Ltd
- Publication Year :
- 2021
-
Abstract
- Background: Ecstasy (3,4-methylenedioxymethamphetamine (MDMA)) has a relatively low harm and low dependence liability but is scheduled on List I of the Dutch Opium Act (‘hard drugs’). Concerns surrounding increasing MDMA-related criminality coupled with the possibly inappropriate scheduling of MDMA initiated a debate to revise the current Dutch ecstasy policy. Methods: An interdisciplinary group of 18 experts on health, social harms and drug criminality and law enforcement reformulated the science-based Dutch MDMA policy using multi-decision multi-criterion decision analysis (MD-MCDA). The experts collectively formulated policy instruments and rated their effects on 25 outcome criteria, including health, criminality, law enforcement and financial issues, thematically grouped in six clusters. Results: The experts scored the effect of 22 policy instruments, each with between two and seven different mutually exclusive options, on 25 outcome criteria. The optimal policy model was defined by the set of 22 policy instrument options which gave the highest overall score on the 25 outcome criteria. Implementation of the optimal policy model, including regulated MDMA sales, decreases health harms, MDMA-related organised crime and environmental damage, as well as increases state revenues and quality of MDMA products and user information. This model was slightly modified to increase its political feasibility. Sensitivity analyses showed that the outcomes of the current MD-MCDA are robust and independent of variability in weight values. Conclusion: The present results provide a feasible and realistic set of policy instrument options to revise the legislation towards a rational MDMA policy that is likely to reduce both adverse (public) health risks and MDMA-related criminal burden.
- Subjects :
- medicine.medical_specialty
MDMA
Substance-Related Disorders
N-Methyl-3,4-methylenedioxyamphetamine
Ecstasy
RANKING
0603 philosophy, ethics and religion
HARM
Decision Support Techniques
03 medical and health sciences
0302 clinical medicine
medicine
Humans
DRUGS
Pharmacology (medical)
030212 general & internal medicine
Policy Making
Psychiatry
Netherlands
Pharmacology
Health Policy
Liability
Opium
risk assessment
06 humanities and the arts
MCDA
Multiple-criteria decision analysis
Original Papers
Psychiatry and Mental health
Harm
Hallucinogens
adverse effects
criminality
Crime
060301 applied ethics
XTC
Risk assessment
Psychology
medicine.drug
Decision analysis
Subjects
Details
- Language :
- English
- ISSN :
- 02698811
- Database :
- OpenAIRE
- Journal :
- Amsterdam, J V, Peters, G-J Y, Pennings, E, Blickman, T, Hollemans, K, Breeksema, J J J, Ramaekers, J G, Maris, C, Bakkum, F V, Nabben, T, Scholten, W, Reitsma, T, Noijen, J, Koning, R & Brink, W V D 2021, ' Developing a new national MDMA policy : Results of a multi-decision multi-criterion decision analysis ', Journal of Psychopharmacology, vol. 35, no. 5, 0269881120981380, pp. 537-546 . https://doi.org/10.1177/0269881120981380, Journal of Psychopharmacology, 35(5):0269881120981380, 537-546. SAGE Publications Ltd, Journal of Psychopharmacology, 35(5), 537-546. SAGE Publications Inc., Journal of psychopharmacology (Oxford, England), 35(5), 537-546. SAGE Publications Ltd, Journal of Psychopharmacology (Oxford, England), Journal of Psychopharmacology, 35(5), 537-546. SAGE Publications Ltd
- Accession number :
- edsair.doi.dedup.....76cf60f794eb5e34ad60b2743bb588d9